ライフサイエンスコーパス: kidney biopsy

1 All patients underwent percutaneous kidney biopsy.

2 osis, and is generally not an indication for kidney biopsy.

3 Rejection status was confirmed by kidney biopsy.

4 ofluorescence and electron microscopy in the kidney biopsy.

5 tinal ischemia occurred, with TMA evident on kidney biopsy.

6 ured in serum collected at enrollment and at kidney biopsy.

7 m 118 consecutive transplant recipients with kidney biopsies.

8 tissue from animal models or biobanked human kidney biopsies.

9 duction using murine AAV models and in human kidney biopsies.

10 s performed to assess the presence of RNS in kidney biopsies.

11 the tubulointerstitial space of human lupus kidney biopsies.

12 quantitation of immune cells in entire human kidney biopsies.

13 as measured annually; 111 subjects underwent kidney biopsies.

14 patients who underwent clinically indicated kidney biopsies, 52 (10%) had diagnosis of TGP.

15 trates universal glomerular abnormalities in kidney biopsies after OLT.

16 nted with proteinuria and renal failure, and kidney biopsy analysis showed a nodular sclerosing GN wi

17 in expression in vivo in inflamed rejecting kidney biopsies and co-expressed in renal tubules.

18 These biopsies and all other kidney biopsies and specimens from the recipients of the

19 tudy was conducted for PV replication in all kidney biopsies and urine cytologies performed between 1

20 In total, 42 kidney biopsies and urine samples were examined.

21 sure for assessing the severity of injury in kidney biopsies and validation for many biomarkers of AK

22 6 patients were collected within 2 months of kidney biopsy and assayed for the urinary biomarkers lip

23 nces of SV40 (but not BK or JC virus) in his kidney biopsy and urine by polymerase chain reaction, So

24 Of these, 2696 donors had both kidneys biopsied and subsequently transplanted.

25 All patients underwent transplant kidney biopsy, and their estimated glomerular filtration

26 ue burden of post-HCT PVN is unknown because kidney biopsies are avoided due to their bleeding risk.

27 Kidney biopsies are being used to evaluate marginal dono

28 enal injury and limited chronicity on pre-LT kidney biopsy are unclear.

29 , D did not vary significantly between human kidney biopsies at the time of transplantation, 3-6 mont

30 during donor evaluation and who underwent a kidney biopsy at donation.

31 Kidney biopsy at the time of recurrence showed mesangial

32 mg/day or a history of amyloidosis underwent kidney biopsies between June 2001 and March 2009.

33 d, is a near universal finding in transplant kidney biopsies by the end of the first decade posttrans

34 This analysis suggests that transplanted kidney biopsies can be performed with minimal risks in p

35 ed age older than 50 years, performance of a kidney biopsy, cytomegalovirus seropositive status, dona

36 subset of African American subjects for whom kidney-biopsy data were available, progression to ESRD w

37 donor CrCl does, and percentage GS on donor kidney biopsies does not, correlate well with 1-year gra

38 Only 4 of the 10 who underwent kidney biopsy donated (two normal, two TBMN).

39 The goal of this study was to characterize kidney biopsy findings in this population and follow the

40 demographic and clinical characteristics and kidney-biopsy findings in humans is unknown.

41 ctors for chronic kidney disease and certain kidney-biopsy findings.

42 mited information about the role of protocol kidney biopsies for de novo donor-specific antibodies (d

43 outcomes of 41 LT recipients who had pre-LT kidney biopsy for unexplained renal dysfunction, protein

44 We measured several renal structures in kidney biopsies from 94 normoalbuminuric patients with l

45 genes in glomeruli and tubulointerstitium in kidney biopsies from diabetic nephropathy patients to id

46 e examined Nox5 expression and regulation in kidney biopsies from diabetic patients, cultured human p

47 ed podocytes in murine models of disease and kidney biopsies from glomerulosclerosis patients exhibit

48 den MPs adherent to capillary endothelium in kidney biopsies from hyperalbuminuric SCD patients.

49 ng for total and phospho-SYK in glomeruli of kidney biopsies from IgAN patients strongly suggests the

50 s well as Hsp60 is significantly elevated in kidney biopsies from individuals undergoing acute and ch

51 Immunohistochemical analyses of kidney biopsies from liver transplant recipients with ch

52 atients but not in normal salivary glands or kidney biopsies from lupus nephritis patients.

53 We examined kidney biopsies from patients with ACTN4 mutations to ch

54 lated from HIV transgenic mice as well as in kidney biopsies from patients with HIV-associated nephro

55 Consistently, kidney biopsies from patients with IgA nephropathy and d

56 In contrast, all 16 kidney biopsies from patients with inflammatory processe

57 Here, we compared miR expression in kidney biopsies from patients with lupus nephritis and i

58 a1 integrin, which was similarly observed in kidney biopsies from patients.

59 Kidney biopsies from Pima Indians with type II diabetes

60 ls in sclerosing and collapsing lesions in a kidney biopsy from a patient with diabetes underscores t

61 ndardized histological grading of transplant kidney biopsies has become a primary criterion for diagn

62 Kidney biopsy has been recommended to guide kidney alloc

63 nclusion, careful quantitative assessment of kidney biopsies in normoalbuminuric patients with type 1

64 factor-beta1, and interleukin-6 in 95 human kidney biopsies in patients with renal failure and mild

65 ity, occurring in approximately 1% of native kidney biopsies in several large biopsy series obtained

66 tle data exist to validate the usefulness of kidney biopsies in this patient population.

67 Kidney biopsy in the remaining 10 showed: two normal; fo

68 eter obstruction model and in human diseased kidney biopsies, in which overlap of PEC- or podocyte-sp

69 Kidney biopsy is considered the golden criterion for dia

70 Kidney biopsy is frequently unhelpful, whereas genetic l

71 ls in the incipient stage of disease, when a kidney biopsy is not yet clinically indicated.

72 A kidney biopsy is often abnormal and aids in the decision

73 Toward this, kidney biopsies (n=100) were cultured in the presence of

74 Renal involvement (n = 7) was established by kidney biopsy (n = 5) or by two or more of the following

75 In human kidney biopsies, Nox5 was identified to be expressed in

76 Glomerular diseases were observed in kidney biopsies obtained during the acute and chronic ph

77 tting, we noted a reduction in SIRT1 mRNA in kidney biopsies obtained from individuals with focal glo

78 Zero-time kidney biopsies, obtained at time of transplantation, ar

79 munohistochemistry in kidneys of Tg mice and kidney biopsies of patients with IgA nephropathy and CKD

80 ermore, IL-17(+) and DN T cells are found in kidney biopsies of patients with lupus nephritis.

81 thin the gene expression profiles from whole kidney biopsies of patients with SLE.

82 uses of renal dysfunction is lacking, with a kidney biopsy often being required.

83 ), and the presence of arterial sclerosis on kidney biopsy (P = 0.0076) when controlling for age, ANC

84 sed transcriptional profile of the zero-hour kidney biopsy predicts posttransplant clinical outcomes

85 ients with minimal chronic changes on pre-LT kidney biopsy recovered kidney function within 1 month f

86 of GN, with a major aim of standardizing the kidney biopsy report of GN.

87 -based classification forms the basis of the kidney biopsy report.

88 ry values were not remarkable, and liver and kidney biopsy results were normal.

89 ntensified immunosuppression (IIS), 1155 had kidney biopsy results, and 212 had an established geneti

90 Kidney biopsy revealed enlarged glomeruli with mesangial

91 Ultrasound and kidney biopsy revealed small dysplastic kidneys with cys

92 Kidney biopsy samples can show definitive evidence of CK

93 Sixty-five posttransplantation kidney biopsy samples covering 41 cases with acute rejec

94 In kidney biopsy samples from patients with nephropathic cy

95 us loads were measured in urine, plasma, and kidney biopsy samples in three clinical settings: (i) pa

96 profiles of 28 TGP and 11 normal transplant kidney biopsy samples were analyzed by Affymetrix HuGene

97 BKVN and normal transplant kidney biopsy samples, and whole blood samples of patien

98 s in FSGS both in rodent models and in human kidney biopsy samples.

99 d in 8 of 11 human liver samples, but 0 of 4 kidney biopsy samples.

100 of gene-expression changes in human diabetic kidney biopsy samples.

101 Healthy living donor kidney biopsies served as controls.

102 All allograft kidney biopsies showed bright C3 staining (2-3+), with s

103 Histologic analysis of kidney biopsies showed EC loss after reperfusion.

104 Transplant kidney biopsy showed acute tubular necrosis in patient 2

105 Donor kidney biopsies showing microvascular thrombosis were id

106 In a human HIVAN kidney biopsy, sidekick expression was increased in glom

107 Examination of the kidney biopsy specimen revealed glomerular deposition of

108 ction, histological evidence of rejection in kidney biopsy specimens and anti-donor reactivity in CML

109 Finally, immunostaining in kidney biopsy specimens demonstrated overexpression of S

110 li and proximal tubules from 98 human needle kidney biopsy specimens for microRNA expression analysis

111 In kidney biopsy specimens from 157 European subjects repre

112 Thirty kidney biopsy specimens from children with idiopathic ea

113 rate upregulation of anillin in podocytes in kidney biopsy specimens from individuals with FSGS and k

114 nd protein S immunostaining was performed on kidney biopsy specimens from patients with diabetic neph

115 We report the induction of podocyte B7-1 in kidney biopsy specimens from patients with type 2 diabet

116 From a cohort of 771 kidney biopsy specimens from two North American and five

117 By analyzing kidney biopsy specimens of patients with extracapillary

118 mistry revealed CCR6-bearing Treg17 cells in kidney biopsy specimens of patients with GN.

119 We performed a meta-analysis in human kidney biopsy specimens with CAI, incorporating data ava

120 V DNA was found in 7 (36.8%) of 19 allograft kidney biopsy specimens with viral nephropathy and 0 (0%

121 is (CML) assays, had absence of rejection in kidney biopsy specimens, and did not develop anti-donor

122 nd C5b-9 are found in immune deposits of IMN kidney biopsy specimens, but the pathway of complement a

123 Compared with normal kidney biopsy specimens, kidney specimens from patients

124 r other kidney grafts or podocytes of native kidney biopsy specimens.

125 f glomerular volume occupied by mesangium in kidney-biopsy specimens.

126 ria with B7-1 immunostaining of podocytes in kidney-biopsy specimens.

127 Also, the use of frequent surveillance kidney biopsies, surrogate markers of chronic rejection,

128 and proteinuria (2-4 g/day) and underwent a kidney biopsy that revealed FSGS-like lesions with arter

129 rf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients

130 gh Resolution Respirometry and fresh porcine kidney biopsies to assess mitochondrial function we show

131 The median time from native kidney biopsy to dialysis or transplantation was 42.3 mo

132 ipose biopsies using real-time RT-PCR and 61 kidney biopsies using the Affymetrix U133 array.

133 Total RNA from kidney biopsies was isolated at 3 clinical time points f

134 at the time of initial diagnosis of C3GN at kidney biopsy was 20.8 years.

135 A kidney biopsy was performed when viremia exceeded 10 cop

136 kable, and if they still wished to donate, a kidney biopsy was performed.

137 From 230 consecutive donor kidney biopsies, we identified eight cases exhibiting do

138 uring the 2-year follow-up blood, urine, and kidney biopsies were collected from 48 renal transplant

139 es, complete blood count, weight, liver, and kidney biopsies were examined for immunotoxin-related ch

140 ofiles of human orthologs of the 43 genes in kidney biopsies were highly significantly related (R(2)

141 Kidney biopsies were obtained before cardiac death and a

142 Kidney biopsies were obtained from 74 patients (control

143 Kidney biopsies were obtained from patients with high pr

144 Kidney biopsies were performed at the end of the trial.

145 Few kidney biopsies were performed.

146 A total of 554 kidney biopsies were taken from donation after brain dea

147 Blood and urine samples and kidney biopsies were then obtained.

148 stitial inflammation and fibrosis is through kidney biopsy, which is invasive and cannot be repeated

149 The gold standard test is kidney biopsy, which is invasive and costly.

150 biopsies (n=3) compared to normal transplant kidney biopsies with (n=3) and without BK viremia (n=11)

151 underlying molecular mechanisms, we analyzed kidney biopsies with and without PVAN.

152 All 11 of the kidney biopsies with AR were positive, as were the 11 AT

153 itive, as were the 11 ATN cases, 9 of the 11 kidney biopsies with CR, and 7 of the 10 with ACR.

154 rescence analysis of a frozen section of her kidney biopsy with antihuman IgG showed staining of the

155 re defined as having any of the following: a kidney biopsy with PV associated nephropathy, any urine

156 scriptions of adverse events associated with kidney biopsies, with choices limited to none, gross hem

157 January 2014 and February 2017 who underwent kidney biopsy within 60 days of detection of dnDSA.

158 tive protocol (84.3%) and indication (15.7%) kidney biopsies yielded 8.1 +/- 4.1 samples per patient,